Trial Profile
A Study to Evaluate the Efficacy and Safety of Pravastatin/Fenofibrate Complex in Patients With Combined Dyslipidemia With Adequately Controlled LDL-C But Inadequately Controlled Triglyceride Level by Atorvastatin Monotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Fenofibrate/pravastatin (Primary) ; Atorvastatin
- Indications Dyslipidaemias
- Focus Registrational; Therapeutic Use
- Acronyms PRADA
- Sponsors Yoo Young Pharmaceutical
- 27 Sep 2018 Status changed from recruiting to completed.
- 30 Aug 2017 Planned number of patients changed from 366 to 302.
- 20 Jun 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.